Stock listing

Ryvu Therapeutics Sa

Selected listing: A1JUH2 · LS · EUR · DE

Ryvu Therapeutics Sa (Lang & Schwarz: A1JUH2), Health Technology. Latest release May 16, 2024: Ryvu Therapeutics First Quarter 2024 Financial Results…

A1JUH2:LSEURDEUpdated September 25, 2026

Ticker: Lang & Schwarz: A1JUH2
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Ryvu Therapeutics Sa

Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

May 16, 2024

Ryvu Therapeutics - Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes

October 23, 2023

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

October 23, 2023

Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

December 22, 2022

Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 24, 2022

All Ryvu Therapeutics Sa news →

Research Ryvu Therapeutics Sa

Ryvu Therapeutics Sa company profile

View the public company page for Ryvu Therapeutics Sa on 6ix.

Ryvu Therapeutics Sa news

Read company news and market updates connected to Ryvu Therapeutics Sa.

Ryvu Therapeutics Sa investor events

Find investor webinars, events, and replay context for Ryvu Therapeutics Sa.